Pfizer enlarges market defense position through high-volume Celebrex
Pfizer Korea has targeted generics of Celebrex(celecoxib), a blockbuster treatment, by volume diversification. Its high-volume 400mg product has been newly approved, and the 100mg product is also planned to be launched.
The Ministry of Food and Drug Safety(MFDS) approved commercialization of Cel...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
